PercipEnz Releases OnCore Clinical and Translational Research Software, Version 10.0
This year’s release of the OnCore Clinical and Translational Research Software, Version 10.0, incorporates work done in eight collaborative projects with research organizations across the country.
“What we’re especially excited about with this version is bringing together the work that has been going on in several collaborative initiatives and making it available to all the OnCore centers,"said Anthony O’Hare, PhD, Chief Scientific Officer at PercipEnz Technologies, Inc., creators of OnCore.
Version 10.0 includes functionality that was previously only available to research centers who were participating in specific collaborative initiatives. New functionality in OnCore includes support for multi-center trials, a new Affiliate Network Administration portal, enhanced communication and reporting tools, and additions to the OnCore Software Developers Toolkit (SDK) for integration with other systems such as those for electronic IRB management.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.
